Latest Breaking News On - Austin murtagh - Page 4 : comparemela.com

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist,. -August 11, 2023 at 06:01 am- MarketScreener

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2022 Earnings Call Transcript

Operator: Greetings, and welcome to Avadel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Call. It is now my pleasure to introduce Austin Murtagh with Stern Investor Relations. Thank you.

Akero Therapeutics Announces Positive End-of-Phase 2

The planned Phase 3 program consists of three trials, SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes to evaluate the safety and.

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results